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Bacterial ABC transporters are an important class of transmembrane transporters that have a wide variety
of substrates and are important for the virulence of several bacterial pathogens, including Streptococcus
pneumoniae. However, many S. pneumoniae ABC transporters have yet to be investigated for their role in
virulence. Using insertional duplication mutagenesis mutants, we investigated the effects on virulence and in
vitro growth of disruption of 9 S. pneumoniae ABC transporters. Several were partially attenuated in virulence
compared to the wild-type parental strain in mouse models of infection. For one ABC transporter, required for
full virulence and termed LivJHMGF due to its similarity to branched-chain amino acid (BCAA) transporters,
a deletion mutant (livHMGF) was constructed to investigate its phenotype in more detail. When tested by
competitive infection, the livHMGF strain had reduced virulence in models of both pneumonia and septicemia
but was fully virulent when tested using noncompetitive experiments. The livHMGF strain had no detectable
growth defect in defined or complete laboratory media. Recombinant LivJ, the substrate binding component of
the LivJHMGF, was shown by both radioactive binding experiments and tryptophan fluorescence spectroscopy
to specifically bind to leucine, isoleucine, and valine, confirming that the LivJHMGF substrates are BCAAs.
These data demonstrate a previously unsuspected role for BCAA transport during infection for S. pneumoniae
and provide more evidence that functioning ABC transporters are required for the full virulence of bacterial
pathogens.
Bacterial ABC transporters are an important class of trans-
membrane transporters that are involved in the import and
export of a wide variety of substrates, including sugars, amino
acids, peptides, polyamines, and cations (11, 12, 17, 39). A
typical ABC transporter consists of four membrane-associated
proteins consisting of two ATP-binding proteins (ATPases)
and two membrane-spanning proteins (permeases) (11, 17).
These may be fused in a variety of ways to form multidomain
polypeptides, but typically permeases consist of six putative -
helical transmembrane segments that act as a channel through
which substrates are transported across the membrane (11,
17). ABC transporters that import their substrate also contain
a substrate-binding protein (SBP) that is present in the
periplasm of gram-negative bacteria and most often as a lipo-
protein bound to the outer surface of the membrane in gram-
positive bacteria (17). These SBPs bind to the substrate before
it is transferred across the cell membrane and therefore confer
substrate specificity for the ABC transporter. Approximately
5% of the Escherichia coli and Bacillus subtilis genomes encode
components of ABC transporters, highlighting the importance
of ABC transporters for the physiology of both gram-positive
and gram-negative bacteria (12, 30). ABC transporters are
known to influence many cellular processes. including antibi-
otic resistance, nutrient acquisition, adhesion, protein secre-
tion, environmental sensing, spore formation, conjugation, and
growth under stress conditions (39). As a consequence, many
ABC transporters have been shown by signature-tagged mu-
tagenesis (STM) screens to be important for the virulence of a
range of bacterial pathogens, including Yersinia spp., Staphy-
lococcus aureus, and Streptococcus pneumoniae (9, 15, 22, 26),
and these data have been supported by publications on the
functions of individual ABC transporters (6, 7, 38, 45).
The annotated genome sequence of the TIGR4 strain of the
common gram-positive pathogen S. pneumoniae contains 73
ABC transporters (4, 13). Several ABC transporters required
for substrate uptake have been described in some detail pre-
viously, and some of these are known to be important for full
virulence, including the cation transporters PsaA, PiuA, PiaA,
and PitA (6, 7, 27, 34) and the polyamine transporter PotABCD
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(44). Why disruption of these ABC transporter functions affect
virulence is probably due to a variety of mechanisms. These
include effects on micronutrient acquisition under stress con-
ditions, such as reduced iron uptake after disruption of PiuA,
PiaA, and PitA; increased sensitivity to oxidative stress due to
loss of polyamine or manganese uptake by PotABCD or PsaA,
respectively (25, 43, 44); and impaired adhesion to cell surfaces
related to disruption of PsaA (2, 20). In addition, since intra-
cellular levels of cations and other micronutrients can influ-
ence gene regulation (20), impaired uptake of micronutrients
could affect bacterial adaptation to the host environment. SBP
components of ABC transporters are attached to the external
surface of the bacterial membrane, where they are exposed to
interactions with the environment, and their sequences are
usually highly conserved between different strains of the same
bacterial species. As a consequence, SBPs have been inves-
tigated as potential protein vaccine candidates, and PiuA,
PiaA, PsaA, and PotD have all been shown to be effective
vaccines in animal models at preventing S. pneumoniae in-
fection (12, 23).
Given the importance of acquisition of various minerals and
nutritional substrates for bacterial growth and virulence in
vivo, some of the S. pneumoniae ABC transporters that have
not yet been investigated are also likely to influence the patho-
genesis of S. pneumoniae infections. Using mouse models of
infection, we have therefore assessed the potential role during
virulence of nine S. pneumoniae ABC transporters that have
not, as far as we are aware, previously been investigated. Sev-
eral ABC transporters were identified as required for full S.
pneumoniae virulence in models of septicemia or pneumo-
nia. The function of one of these ABC transporters, termed
livJHMGF, which BLAST searches suggest is a member of the
hydrophobic amino acid transporter subfamily and is likely to
be a branched-chain amino acid (BCAA) transporter (40), was
investigated in more detail.
MATERIALS AND METHODS
Bacterial strains, media, and growth conditions. The E. coli strains DH5,
Novablue competent cells (Novagen), JM109 (Promega), and M15 (Qiagen)
were used for cloning procedures. The capsular serotype 3 S. pneumoniae strain
0100993, originally isolated from a patient with pneumonia and obtained from
SmithKline Beecham, Plc. (22), was used to construct S. pneumoniae mutant
strains for the majority of the in vitro and in vivo phenotype analysis, with
additional experiments performed using the capsular serotype 2 strain D39 and
the serotype 4 strain TIGR4. E. coli was cultured at 37°C using Luria-Bertani
broth or agar plates, and S. pneumoniae strains were cultured in the presence of
5% CO2 at 37°C on Columbia agar (Oxoid) supplemented with 5% horse blood
(TCS Biosciences) or in Todd-Hewitt broth supplemented with 0.5% yeast-
extract (Oxoid) or CDEM medium (42). Plasmids and mutant strains were
selected for using appropriate antibiotics (10 g of chloramphenicol, 100 g of
carbenicillin, and 25 g of kanamycin ml1 for E. coli and 10 g of chloram-
phenicol and 0.2 g of erythromycin ml1 for S. pneumoniae). Stocks of S.
pneumoniae were stored as single-use 0.5-ml aliquots of THY broth culture
(optical density at 580 nm [OD580] of 0.3 to 0.4) at 70°C in 10% glycerol. The
growth of S. pneumoniae strains in broth was monitored by measuring the OD580.
Nucleic acid manipulations and RT-PCR. S. pneumoniae genomic DNA was
extracted from bacteria grown in THY by using a modified Wizard genomic
DNA kit (Promega), and RNA was extracted by using an SV total RNA extrac-
tion kit (Promega) as previously described (6). Restriction digests, ligation of
DNA fragments, fractionation of DNA fragments by electrophoresis, and trans-
formation of E. coli (by heat shock) were performed according to established
protocols (33). DNA fragments were purified from electrophoresis gels by using
a QIAquick gel extraction kit. Reverse transcriptase PCR (RT-PCR) was per-
formed by using the Access RT-PCR system (Promega) and gene-specific prim-
ers (see Table 2). The National Center for Biotechnology Information website
(http://www.ncbi.nlm.nih.gov/blast) was used to perform BLAST searches and
alignments of the available complete and incomplete bacterial nucleotide and
protein databases. Primers for both PCR and RT-PCR were designed using
sequences displayed by the Artemis software.
Construction of S. pneumoniae mutant strains. Strains and plasmids used for
the present study are described in Table 1, and the primers used for PCR and
sequencing are listed in Table 2. Strains containing disrupted copies of genes
encoding ABC transporters were constructed by using insertional duplication
mutagenesis (IDM) and the plasmid pID701 (22). Internal fragments of target
genes were amplified by PCR from S. pneumoniae genomic DNA using primers
designed from the TIGR4 genome sequence (Table 2) (http://www.tigr.org) (40).
Amplified products were ligated into the XbaI site of pID701 and transformed
into E. coli for amplification of plasmid DNA. Plasmids with the correct inserts
were then used to transform S. pneumoniae strain 0100993 using competence
stimulating peptide 1 (kindly provided by D. Morrison) and selection with chlor-
amphenicol according to established protocols (6, 22).
The livHMGF strain was constructed by overlap extension PCR (36) using a
transformation fragment in which a contiguous fragment of S. pneumoniae
genomic DNA from Sp0749 to Sp0754 had the genes livHMGF (Sp0750 to
Sp0753) replaced by the erythromycin resistance cassette ery. Two products
corresponding to 883 kb 5 (primers Sp0749F and Ery-Sp0749R) and 833 kb 3
(primers Ery-Sp0753F and Sp0754R) to livHMGF were amplified from S. pneu-
moniae genomic DNA by PCR carrying 3 and 5 linkers complementary to the
5 and 3 portion of the ery gene, respectively. ery was amplified from pACH74
using PCR and the primers EryF and EryR (21). Reaction conditions for am-
plifying these three fragments were as follows: a volume of 200 l containing 100
pmol of primers, 200 M deoxynucleoside triphosphates (dNTPs; Bioline), and
0.5 U of Taq DNA polymerase (Sigma) using an initial denaturing step at 94°C
for 4 min, followed by a PCR cycle of 94°C for 30 s, 55°C for 45 s, and 72°C for
1 min for 30 cycles, with a final extension at 72°C for 10 min. Cleaned individual
PCR products were fused by using a two-step PCR, with an initial PCR to fuse
the 5-flanking DNA fragment with ery, followed by addition of the 3-flanking
DNA. The conditions for the first PCR were as follows: reaction volume of 20 l
containing 8.7 l of nuclease free water, 1 l of buffer, 1 l of 2 mM dNTPs, 0.4
l of 50 mM MgSO4, 0.2 l of Taq polymerase (Bioline), and approximately 50
ng of each PCR product with no primers and an initial denaturing step at 94°C
for 2 min, followed by 10 cycles of 94°C for 20 s, 50°C for 30 s, and 72°C for 1 min.
The conditions for the second PCR were as follows: a reaction volume of 100 l
containing 68.2 l of nuclease-free water, 10 l of buffer, 10 l of 2 mM
concentrations of dNTPs, 4 l of 50 mM MgSO4, 100 pmol of primers Sp0749F
and Sp0754R, 3 l of unpurified PCR product from the first PCR, and 0.8 l of
Taq polymerase and an initial denaturing step at 94°C for 2 min, followed by 35
cycles of 94°C for 20 s, 50°C for 30 s, and 72°C for 2.5 min, with a final extension
at 72°C for 3 min. The fusion PCR products were then analyzed on a 1% agarose
gel, and the desired DNA band was excised and purified by using Qiagen
QIAquick columns and transformed into the S. pneumoniae 0100993, D39, and
TIGR4 strains as described above (7, 22). Plasmid and S. pneumoniae mutant
identities were confirmed by PCR using insert (Table 2) and plasmid-specific
primers (Sp1 and Sp3), followed by sequencing of the PCR products (performed
by Lark Technologies, Inc. [United Kingdom] or UCL Sequencing Services using
the BigDye terminator technique and gene-specific PCR primers).
Expression and characterization of His6-LivJ lipoprotein. The lipoprotein
LivJ (Sp0749) was expressed in E. coli and purified by using an N-terminal His-
tagged QIAexpressionist system (Qiagen). Primers Sp0749Fwd and Sp0749Rv
amplified a full-length livJ (excluding the 5 portion encoding the predicted
N-terminal signal peptide), which was ligated into the pQE30 expression vector
to make the plasmid pPC139 and transformed into E. coli strain M15. Pro-
tein expression was induced with IPTG (isopropyl--D-thiogalactopyranoside)
and native His6-LivJ purified using Ni-NTA affinity columns according to the
QIAexpressionist manual. Purification products were analyzed by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis and shown to contain a 95%
purity of protein of the expected size for His6-LivJ, and the identity of the
recombinant protein was confirmed by peptide mass fingerprinting as reported
previously (35).
[14C]leucine, [14C]isoleucine, and [14C]maltose uptake and binding assays.
Radioactive uptake assays were performed by the rapid filtration method as
previously described (45) with minor modifications. S. pneumoniae strains were
grown in THY medium until the OD620 reached 0.2 to 0.4. These experiments
were performed using a capsular serotype 2 S. pneumoniae strain (D39) since the
mucoid colonies of the capsular serotype 3 strain prevented effective pelleting of
the bacteria for these assays. Bacteria were harvested at 13,000  g for 20 min
and resuspended in 50 mM potassium phosphate buffer (pH 7.2) with 1 mM
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MgCl2 to an OD620 between 0.8 and 1.1. The uptakes of leucine, isoleucine, and
maltose were determined in 1-ml assays containing 0.85 ml of bacterial cells and
a final concentration of 25 M maltose, isoleucine, or leucine containing 0.125
Ci of 14C-labeled substrate ([14C]isoleucine, [14C]leucine, and [14C]maltose;
GE Healthcare, United Kingdom). Samples (150 l) containing bacteria and
radioactive and nonradioactive substrates were removed at various time intervals
(0, 1, 2, and 3 min) and immediately filtered through glass fiber filters (Whatman
GF/F) and washed twice with 50 mM potassium phosphate buffer. The washed
filters were placed in scintillation vials in 5 ml of Ready-Safe scintillation cocktail
(Beckman Coulter), and the radioactivity was determined by using a Wallac 1214
RackBeta liquid scintillation counter. A bicinchoninic acid protein assay (Sigma
Aldrich, United Kingdom) determined that an OD620 of 1 was equivalent to
0.238 mg of protein, and this figure was used to convert the radioactivity counts
to nmol of solute per mg of protein.
For radioactive substrate binding assays, 100 l of purified His6-LivJ (27.5 g)
was incubated with a 5 M substrate containing 0.1 Ci of 14C-labeled ligand
(GE Healthcare) and further incubated on ice for 10 min. To this mixture, 1 ml
of saturated ammonium sulfate was added, followed by incubation on ice for 20
min, and then filtered onto glass fiber filter papers (GF/F; Whatman). The filters
were then washed with 4 ml of saturated ammonium sulfate and dried for 5 min.
The filters were allowed to equilibrate in Ready-Safe scintillation cocktail for 20
min, and the radioactivity was determined by using a Wallac 1214 RackBeta
liquid scintillation counter (31).
Tryptophan fluorescence spectroscopy. Purified His6-LivJ was used for tryp-
tophan fluorescence spectroscopy using a Hitachi F-2500 spectrofluorimeter at
an excitation wavelength of 280 nm (slit width, 3 nm) and an emission wavelength
of 309 nm (slit width, 3 nm) (41). The assay was performed by adding test amino
acids (Sigma) dissolved in 10 mM NaH2PO4 to 0.5 M His6-LivJ in 1.5 ml of 50
mM Tris-HCl (pH 8) in a sample cuvette maintained at 25°C in the spectrofluo-
rimeter with continuous stirring. The slit width of the spectrofluorimeter was
adjusted to reduce photobleaching of the protein (41).
Animal models of infection. Infection experiments were performed in age- and
sex-matched groups of outbred CD1 mice (Charles River Breeders) between 4 to
8 weeks old. For mixed infections, equivalent numbers of bacteria from stocks of
wild-type and mutant S. pneumoniae strains were mixed and diluted to the
appropriate concentration. For the nasopharyneal colonization model, 107 CFU
of bacteria in 10 l were administered by intranasal (i.n.) inoculation under
halothane general anesthesia, and nasal washes were obtained after 2 days. For
the systemic model of infection, 103 CFU of bacteria in 100 l were inoculated
by intraperitoneal (i.p.) injection, and spleen homogenates were obtained at 24 h
(6, 21). For the pneumonia model, 5  106 CFU of bacteria in 40 l were given
by i.n. inoculation under halothane general anesthesia, and lung and spleen
homogenates were obtained at 48 h (8, 21). Aliquots from samples recovered
from mice were plated on plain and Cm containing plates to allow calculation of
a competitive index (CI). The CI was calculated as follows: the ratio of mutant
to wild-type strain recovered from mice divided by the ratio of mutant to wild-
type strain in the inoculum (5). A CI of 	1 indicates that the mutant strain is
attenuated in virulence compared to the wild-type strain, and the lower the CI
the more attenuated the mutant strain. Similar experiments were performed with
a pure inocula of wild-type or livHMGF strain bacteria to calculate the bacterial
CFU for each strain at specific time points or to monitor the progress of infection
identifying mice likely to progress to fatal disease according to previously estab-
lished criteria (6).
Statistical analysis. All of the in vitro growth curves were performed in
triplicates and are represented as means and standard deviations. The results of
growth curves, radioactive uptake, and binding assays were analyzed by using
two-tailed Student t tests. The results of survival experiments were compared by
using the log-rank method, and target organ CFU levels were analyzed by using
the Mann-Whitney U test. The statistical validity of the results for CIs is repre-
sented by 95% confidence intervals.
RESULTS
Selection of ABC transporters for investigation. The ABC
transporters chosen for these studies were identified from the
annotated genome of the capsular serotype 4 strain of S. pneu-
moniae (TIGR4) (40). This genome contains 24 loci consisting
of three or more adjacent genes that encode putative com-
ponents of ABC transporters and are likely to be transcribed
as an operon, 10 of which have been previously investigated.
Eleven of the previously undescribed ABC transporters
TABLE 1. Strains and plasmids constructed and/or used in this study
Plasmid or strain Description (source or reference)a
Plasmids
pID701 .......................................................................................Shuttle vector for IDM transformation of S. pneumoniae: Cmr (22)
pPC110 ......................................................................................pID701 containing an internal portion of Sp0090 in the XbaI site: Cmr (this study)
pPC111 ......................................................................................pID701 containing an internal portion of Sp0149 in the XbaI site: Cmr (this study)
pPC112 ......................................................................................pID701 containing an internal portion of Sp0610 in the XbaI site: Cmr (this study)
pPC113 ......................................................................................pID701 containing an internal portion of Sp0710 in the XbaI site: Cmr (this study)
pPC114 ......................................................................................pID701 containing an internal portion of Sp1796 in the XbaI site: Cmr (this study)
pPC115 ......................................................................................pID701 containing an internal portion of Sp1824 in the XbaI site: Cmr (this study)
pPC116 ......................................................................................pID701 containing an internal portion of Sp0750 in the XbaI site: Cmr (this study)
pPC117 ......................................................................................pID701 containing an internal portion of Sp1690 in the XbaI site: Cmr (this study)
pPC118 ......................................................................................pID701 containing an internal portion of Sp0846 in the XbaI site: Cmr (this study)
pPC119 ......................................................................................pID701 containing an internal portion of Sp2084 in the XbaI site: Cmr (this study)
pPC120 ......................................................................................pID701 containing an internal portion of Sp2108 in the XbaI site: Cmr (this study)
pPC139 ......................................................................................pQE30 carrying full length livJ: Kmr Ampr (this study)
Strains
0100993......................................................................................S. pneumoniae capsular serotype 3 clinical isolate (22)
Sp0090.....................................................................................0100993 containing an insertion made with plasmid pPC110: Cmr (this study)
Sp0149.....................................................................................0100993 containing an insertion made with plasmid pPC111: Cmr (this study)
Sp0610.....................................................................................0100993 containing an insertion made with plasmid pPC112: Cmr (this study)
Sp0750.....................................................................................0100993 containing an insertion made with plasmid pPC116: Cmr (this study)
Sp0846.....................................................................................0100993 containing an insertion made with plasmid pPC118: Cmr (this study)
Sp1690.....................................................................................0100993 containing an insertion made with plasmid pPC117: Cmr (this study)
Sp1796.....................................................................................0100993 containing an insertion made with plasmid pPC114: Cmr (this study)
Sp1824.....................................................................................0100993 containing an insertion made with plasmid pPC115: Cmr (this study)
Sp2084.....................................................................................0100993 containing an insertion made with plasmid pPC119: Cmr (this study)
Sp2108.....................................................................................0100993 containing an insertion made with plasmid pPC120: Cmr (this study)
livHMGF .................................................................................0100993 containing the livHMGF deletion construct: Ermr (this study)
T4livHMGF.............................................................................TIGR4 containing the livHMGF deletion construct: Ermr (this study)
a Cmr, chloramphenicol resistance; Kmr, kanamycin resistance; Ermr, erythromycin resistance.
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present in the TIGR4 genome of S. pneumoniae were se-
lected for further investigation (Sp0090-3, Sp0148-52, Sp0607-10,
Sp0708-11, Sp0749-53, Sp0846-8, Sp1688-90, Sp1796-8, Sp1824-6,
Sp2084-7, and Sp2108-10). The results of BLAST searches
using the derived amino acid sequence for each gene within the
putative operons are shown in Table 3. Most of these ABC
transporter proteins have 
90% identity and similarity at the
amino acid level to proteins encoded by genes in the S. pneu-
moniae R6 strain, an avirulent laboratory strain of S. pneu-
moniae derived from a capsular serotype 2 strain. However,
there are no homologues of the Sp1796-8 operon in the R6
genome, and BLAST searches versus the 18 other available S.
pneumoniae genomes demonstrated that the Sp1796-8 operon
was also absent from the genomes of a further five strains
(CDC1087-00, D39, G54, Hungary 19A-6, and Sp23-BS72). In
contrast, the SBPs for almost all of the remaining ABC trans-
porters were highly conserved between S. pneumoniae strains,
with 97% or greater levels of identity between the deduced
amino acid sequence of the TIGR4 SBP with the sequence of
the equivalent SBP for all 19 S. pneumoniae strains with avail-
able genome data. The exception was Sp1826, which had be-
tween 93 and 95% identity to proteins encoded by genes
present in 18 strains and 99% identity to the remaining strain
(CDC0288-44). As expected, the majority of the predicted
proteins have at least 50% identity and 60% similarity to pro-
teins encoded by other streptococci (Table 3). In contrast, the
genes in the putative Sp1688-90, Sp1824-26, and Sp2084-87
operons have no close homologues in streptococci. Sp1688-90
has 
70% identity and 
85% similarity to the amino acid
sequence of predicted proteins encoded by Pm1760-62 of the
gram-negative bacteria Pasteurella multocida, and Sp1824-26
and Sp2084-87 both have lower levels of identity and similarity
to predicted proteins from a variety of unrelated bacteria. The
mean GC contents of Sp1688-90 and Sp1824-6 are 37 and
33.5%, respectively, which is significantly lower than the GC
content of the complete genome of TIGR4 (39.7%) (6, 40).
The mean GC content of Sp2084-7 was 39.0%, which is not
significantly different from that of the complete genome of
TIGR4. These data suggest that Sp1688-90, Sp1824-6, and
possibly Sp2084-7 are contained within regions of the S. pneu-
moniae genome that could have been acquired by horizontal
transfer from an unrelated species.
Construction of ABC transporter mutant strains. To inves-
tigate the role of the selected ABC transporters during in vivo
growth and virulence, mutant strains of the 0100993 strain of
the capsular serotype 3 S. pneumoniae were constructed by
using IDM. Mutations were designed to disrupt one gene,
usually the first, within the putative operon of each ABC trans-
porter (Fig. 1) and were successfully obtained for 10 of the 11
chosen ABC transporters. Although the disruption construct
was made successfully, no mutants were obtained by disrupting
Sp0710 despite repeated transformations. The stability of each
mutation was assessed by culturing the mutant strains in THY
broth in the absence of antibiotic (and therefore selective pres-
sure) for two 8-h growth cycles, followed by plating onto plain
and antibiotic plates. The Sp2084 mutation was unstable (19
chloramphenicol-resistant colonies recovered compared to

1,000 on plain plates), preventing further investigation of this
mutant, whereas the mutations in the remaining mutant strains
were stable with similar numbers of colonies on the plain and
antibiotic plates. All of the mutant strains had similar growth in
THY compared to the wild-type strain when measured by
monitoring the OD580 over time (data not shown).
Phenotypes of mutant strains containing disruptions in
genes encoding ABC transporters. The phenotypes of the mu-
tant strains were investigated using mixed inocula and CIs to
identify subtle defects affecting in vitro growth and to assess
their virulence compared to the wild-type strain in animal
models of infection. CIs were obtained for growth in complete
medium (THY) and a physiologically relevant fluid (human
blood) and in mouse models of pulmonary and systemic infec-
tion using bacteria recovered from the lungs and spleen, re-
spectively, to calculate the CI (Table 4). We were unable to
establish a nasopharyngeal colonization model for the serotype
3 strain in which the mutants were constructed, preventing
assessment of the role of these ABC transporters during col-
TABLE 2. Primers used in this study
Primer Sequencea
Sp0090.1 ................GCTCTAGACATTGAGAGAGACAACTGG
Sp0090.2 ................CGCTCTAGACAAGAAGTAAGGGAAC
Sp0149.1 ................GCTCTAGAGGCTCTTGCAGCTTGCGG
Sp0149.2 ................CGCTCTAGAGGCTTTCGTTTGTAGCGTC
Sp0610.1 ................GCTCTAGATTACGGAGACTACCACG
Sp0610.2 ................CGCTCTAGATCCACCAGATAGCATGCC
Sp0710.1 ................GCTCTAGATTGGGCGTTACGATTG
Sp0710.2 ................CGCTCTAGAGTGCCTGTCCACTTTC
Sp0750.1 ................GCTCTAGACGCGCTGTTAGCCCTAGG
Sp0750.2 ................GCTCTAGATGATACTGCACGCATGGC
Sp846.1 ..................GCTCTAGATGTTAGCAGGCCTTCTTG
Sp846.2 ..................CGCTCTAGAGCCCCTGCAATTTCAAC
Sp1690.1 ................GCTCTAGATTGCGCTAGCGGCTGTTG
Sp1690.2 ................GCTCTAGAGCTTCCTCCACCACTACG
Sp1798.1 ................GCTCTAGATGACTGTCCCCGGTTTAG
Sp1798.2 ................CGCTCTAGATTGTTGATTGGTCCTCCC
Sp1826.1 ................GCTCTAGACGACTGCTTCTTCATCTG
Sp1826.2 ................CGCTCTAGAATTGCCCGTCCTGTACC
Sp2084.1 ................GCTCTAGATTTGGGCTTGTTGCCTG
Sp2084.2 ................CGCTCTAGATGTGACCACTTGTTGACC
Sp2108.1 ................GCTCTAGAACTGCTACACTTGCTAG
Sp2108.2 ................CGCTCTAGAACCAAGGCTACCTAC
Cm.1 ......................TTATAAAAGCCAGTCATTAG
Cm.2 ......................TTTGATTTTTAATGGATAATG
Sp1 .........................TCGAGATCTATCGATGCA
Sp3 .........................GGATCCATATGACGTCGA
EryF.......................ATGAACAAAAATATAAAATA
EryR ......................TTATTTCCTCCCGTTAAATAAT
Sp0749F.................CACTGACAATGCCAGTGACTATGC
Ery-Sp0749R.........TATTTTATATTTTTGTTCATAAGATTCACTC
TTTCTATTTATAA
Ery-Sp0753F .........ATTATTTAACGGGAGGAAATAAAACATTC
CAGTGGATTGTTTTAG
Sp0754R ................GCGGAATATTGACTGTATGGGAG
Sp0749Fwd............CGGGATCCTGTGGAGAAGTGAAGTCTGGA
Sp0749Rv ..............CGGGATCCTTATGGTTTTACAACTTCTGC
Sp0749RT1 ...........CGATGCAGACCACAACAC
Sp750RT2 .............CCTAGGGCTAACAGCGC
750RT1.1...............GATGGGGGTTACTCCAGG
751RT2.1...............CCCAGAGTTGCTACCGC
751RT1.1...............GGTGCGATTGTTTCGG
752RT2.1...............GGTTCCGTAGCAAGGG
Sp0752RT1 ...........GGCCGTTTAATCGCTCAAG
Sp0753RT2 ...........GGGCGCGTCCCATGGCAAG
753RT1.1...............GGAGAATCGTCCTATCAG
754RT2.1...............CAGGCAGACGGTGCAAACC
a Restriction enzyme sites in 5 linkers are underlined.
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onization. Most of the mutants had CIs close to 1.0 in THY,
suggesting that disruption of the target ABC transporters had
no effect on growth in complete medium. The exception was
Sp0750 which had mildly impaired growth in THY. In con-
trast, in normal physiological fluid such as human blood, the
mutants Sp0090, Sp0149, Sp0750, Sp1824, and (to a
lesser extent) Sp0610 had reduced CIs, suggesting that these
mutants have a particular problem growing in physiological
fluid compared to THY. The in vivo CIs for most mutant
strains mirrored the CIs for growth in blood, with these strains
showing no impairment in CI in blood also being fully virulent
(Sp0846, Sp1690, and Sp1796), whereas strains with im-
paired CIs in blood also had a reduced CI during infection.
These data indicate that for these mutant strains, impaired
growth under physiological conditions is associated with a re-
duced ability to cause invasive infection. In addition, Sp2108
had some impairment in virulence after i.p. inoculation with-
out any impairment in CI in growth in blood. For both systemic
and pulmonary infections, the Sp0750 and Sp0149 strains
were markedly more attenuated in virulence than the other
mutant strains with a CI reduced out of proportion to the
reduced CI in blood.
Construction of a deletion mutant of Sp0750-53. The data
obtained with the disruption mutant strains suggested that the
ABC transporters encoded by Sp0149-52 and Sp0749-53 have
the most crucial roles during S. pneumoniae infection (Table
4). BLAST alignments of the predicted proteins encoded by
Sp0149-52 suggested these genes encode a methionine ABC
transporter protein, but the function of this ABC transporter
was not investigated further at this stage (37). BLAST align-
ments of Sp0749-53 showed the proteins encoded by these
genes have high levels of similarity to predicted BCAA ABC
transporter proteins (Table 3), clearly indicating the likely
function of this ABC transporter. Auxotrophy for BCAA due
to mutations affecting BCAA synthesis has been shown to
affect the virulence of Mycobacterium bovis and Burkholderia
TABLE 3. BLAST alignments of the derived amino acid sequences of the investigated S.pneumoniae ABC transporters
Locus taga Size (no. ofamino acids) Protein Organism % Identity/similarity
b Possible substrate (transport
classification)c
Sp0090 319 EfaeDRAFT_2526 Enterococcus faecium 61/80 (311) Sugar (CUT1 3.A.1.1)
Sp0091 307 EfaeDRAFT_2527 Enterococcus faecium 60/79 (300) Sugar (CUT1 3.A.1.1)
Sp0092 491 EfaeDRAFT_2538 Enterococcus faecium 53/70 (486) Sugar (CUT1 3.A.1.1)
Sp0148 276 SMU.1942c Streptococcus mutans 55/76 (237) Methionine (MUT 3.A.1.24)
Sp0149 284 SPs1626 Streptococcus pyogenes 67/81 (278) Methionine (MUT 3.A.1.24)
Sp0150 457 SMU.1940c Streptococcus mutans 70/85 (457) Methionine (MUT 3.A.1.24)
Sp0151 353 SsiuDRAFT_0064 Streptococcus suis 80/90 (352) Methionine (MUT 3.A.1.24)
Sp0152 230 SPs1624 Streptococcus pyogenes 71/89 (230) Methionine (MUT 3.A.1.24)
Sp0607 219 SMU.1522 Streptococcus mutans 74/85 (213) Amino acid (PAAT 3.A.1.3)
Sp0608 219 SMU.1521 Streptococcus mutans 62/81 (222) Amino acid (PAAT 3.A.1.3)
Sp0609 254 StheL01000593 Streptococcus thermophilus 60/73 (232) Amino acid (PAAT 3.A.1.3)
Sp0610 252 StheL01000592 Streptococcus thermophilus 82/90 (251) Amino acid (PAAT 3.A.1.3)
Sp0708 215 SsuiDRAFT_0032 Streptococcus suis 60/77 (209) Amino acid (PAAT 3.A.1.3)
Sp0709 252 SGO_0983 Streptococcus gordonii 88/94 (252) Amino acid (PAAT 3.A.1.3)
Sp0710 225 SGO_0984 Streptococcus gordonii 89/95 (225) Amino acid (PAAT 3.A.1.3)
Sp0711 206 SGO_0985 Streptococcus gordonii 87/94 (226) Amino acid (PAAT 3.A.1.3)
Sp0749 386 SAG1582 Streptococcus agalactiae 53/73 (390) BCAA (HAAT 3.A.1.4)
Sp0750 289 SAK_1597 Streptococcus agalactiae 83/93 (289) BCAA (HAAT 3.A.1.4)
Sp0751 318 gbs1630 Streptococcus agalactiae 73/88 (252) BCAA (HAAT 3.A.1.4)
Sp0752 254 SsuiDRAFT_0078 Streptococcus suis 85/93 (254) BCAA (HAAT 3.A.1.4)
Sp0753 236 SsuiDRAFT_0077 Streptococcus suis 87/96 (236) BCAA (HAAT 3.A.1.4)
Sp0846 511 Spy1227 Streptococcus pyogenes 81/91 (508) Ribonucleoside (CUT2 3.A.1.2)
Sp0847 352 SAK_1051 Streptococcus agalactiae 77/88 (353) Ribonucleoside (CUT2 3.A.1.2)
Sp0848 318 Spy0928 Streptococcus pyogenes 80/92 (318) Ribonucleoside (CUT2 3.A.1.2)
Sp1688 277 PM1760 Pasteurella multocida 80/91 (277) Sugar (CUT1 3.A.1.1)
Sp1689 294 PM1761 Pasteurella multocida 79/93 (291) Sugar (CUT1 3.A.1.1)
Sp1690 445 PM1762 Pasteurella multocida 70/85 (407) Sugar (CUT1 3.A.1.1)
Sp1796 538 SsuiDRAFT_0524 Streptococcus suis 78/89 (537) Sugar (CUT1 3.A.1.1)
Sp1797 305 SsuiDRAFT_0525 Streptococcus suis 82/94 (294) Sugar (CUT1 3.A.1.1)
Sp1798 305 SsuiDRAFT_0526 Streptococcus suis 84/95 (303) Sugar (CUT1 3.A.1.1)
Sp1824 563 Lxx14070 Leifsonia xyli 31/48 (539) Cation 2 (BIT 3.A.1.0)
Sp1825 336 STH2752 Symbiobacterium thermophilum 45/59 (343) Cation 2 (BIT 3.A.1.0)
Sp1826 355 Lxx14040 Leifsonia xyli 30/48 (323) Cation 2 (BIT 3.A.1.0)
Sp2084 291 RUMOBE_00498 Ruminococcus obeum 46/65 (287) Phosphate (PhoT 3.A.1.7)
Sp2085 287 Cthe_1604 Clostridia thermocellum 61/98 (284) Phosphate (PhoT 3.A.1.7)
Sp2086 271 DORLON_00312 Dorea longicatena 59/80 (287) Phosphate (PhoT 3.A.1.7)
Sp2087 250 BACCAP_00261 Bacteroides capillosus 72/86 (253) Phosphate (PhoT 3.A.1.7)
Sp2108 423 M_28Spy1048 Streptococcus pyogenes 53/67 (420) Maltodextrin (CUT1 3.A.1.1)
Sp2109 435 Spy1301 Streptococcus pyogenes 66/82 (430) Maltodextrin (CUT1 3.A.1.1)
Sp2110 280 SsuiDRAFT_0440 Streptococcus suis 85/93 (280) Maltodextrin (CUT1 3.A.1.1)
a That is, the TIGR4 genome locus tag number.
b The length, in amino acids, compared is indicated in parentheses.
c Transport classification and subfamily and number according to the transport classification system based on sequence similarity (32, 45; see also http://www.tcdb
.org/).
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pseudomallei (3, 24) but, as far as we are aware, no role has yet
been described for BCAA transporters in bacterial virulence.
We therefore elected to investigate the Sp0749-53 transporter
in more detail and have named the genes livJHMGF to corre-
spond to their E. coli orthologues (1).
To confirm the genetic organization of Sp0749-0753, RT-
PCR was performed using RNA from strain 0100993 as the
template and primers designed to amplify a product that spans
the junctions of the genes present in the putative operon (Ta-
ble 2). The lack of DNA contamination was confirmed by the
absence of products for reactions with no added RT enzyme
(data not shown), and RT-PCR products were sequenced to
confirm their identities. The livJHMGF/Sp0749-53 region is
4,831 bp in length and consists of five genes, livJ/Sp0749 (en-
coding an SBP lipoprotein), livH/Sp0750 (encoding a mem-
brane protein permease), livM/Sp0751 (encoding a membrane
protein permease), livG/Sp0752 (encoding an ATPase) and
livF/Sp0753 (encoding an ATPase) (Table 3 and Fig. 2A). The
RT-PCR results matched with the operon structure deduced
from the TIGR4 genome sequence, suggesting that livJ is not
cotranscribed with livH (corresponding to the relatively large
intergenic region between these two genes of 268 bp) and that
livH, livM, livG, and livF are all cotranscribed (Fig. 2A and B).
Although the RT-PCR product obtained using primers span-
ning the junction of livM and livG was smaller than the ex-
pected size, sequencing confirmed it represented a product of
the 5 region of livM and 3 region of livG and conformed
exactly in length and almost exactly in nucleotide sequence to
that predicted from the genome data for the TIGR4 strain.
RT-PCR between livF and Sp0754 did generate a cDNA frag-
ment, but sequencing demonstrated this was a nonspecific
product. For further investigation of the function of livJHMGF,
a mutant strain in the S. pneumoniae 0100993 background was
constructed in which livHMGF were deleted using a construct
made by overlap extension PCR (Fig. 2C and D). Correct
deletion of these genes in the livHMGF mutant strain was
confirmed by PCR and sequencing.
In vivo phenotypes of the livHMGF mutant strain. To
investigate the effect of deletion of livHMGF on the virulence
of S. pneumoniae, CIs were determined in the pulmonary and
systemic mouse models of infection. The CIs for the livHMGF
deletion mutant were reduced in models of pneumonia and
septicemia showing a significant attenuation in virulence in
these models of infection (Table 5), although the results were
FIG. 1. Schematic diagram showing the organization of loci encod-
ing ABC transporter components investigated in the present study.
Each arrow represents a single gene, which are not drawn to scale.
Gaps between genes correspond to gaps of greater than 50 bp between
the stop codon of the upstream gene and the ATG of the downstream
gene. The TIGR4 gene number is given above each gene, and whether
the gene encodes a putative SBP, ATPase or membrane protein (per-
mease) is written beneath. The diagonally shaded gene in each locus
(o) was targeted by IDM using pID701 containing an internal portion
of the target gene.
TABLE 4. In vitro and in vivo phenotype analysis of S. pneumoniae ABC transporter mutant strains using CI valuesa
Strain
CI (95% confidence interval) with various sample types
THY Blood i.p. i.n.
Sp0090 1.10 (0.24–2.0) 0.39 (0.31–0.47) 0.49 (0.37–0.61) 0.43 (0.23–0.63)
Sp0149 0.95 (0.67–1.22) 0.46 (0.37–0.57) 0.067 (0.031–0.10) 0.041 (0.021–0.10)
Sp0610 1.40 (1.02–1.77) 0.71 (0.58–0.83) 0.70 (0.53–0.86) 0.64 (0.15–1.20)
Sp0750 1.06 (0.86–1.25) 0.40 (0.20–0.60) 0.17 (0.078–0.26) 0.018 (0.002–0.032)
Sp0846 0.95 (0.67–1.22) 1.25 (0.90–1.60) 0.61 (0.22–1.00) 0.54 (0.30–0.79)
Sp1690 0.97 (0.77–1.18) 0.92 (0.56–1.27) 0.89 (0.41–1.38) NDb
Sp1796 0.82 (0.59–1.04) 0.78 (0.56–0.99) 1.30 (0.93–1.71) ND
Sp1824 0.95 (0.25–1.65) 0.66 (0.43–0.89) 0.59 (0.34–0.84) 0.33 (0.01–0.67)
Sp2108 1.05 (0.71–1.40) 1.25 (0.92–1.57) 0.39 (0.29–0.49) 1.00 (0.36–1.64)
a For mouse experiments, n  3 to 10.
b ND, not done.
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higher than those obtained with the Sp0750 IDM mutant
strain (Table 4). CIs were also obtained for a livHMGF strain
in the TIGR4 background in models of nasopharyngeal colo-
nization, systemic infection, and pneumonia (Table 5). The
TIGR4 livHMGF strain was significantly attenuated in viru-
lence in the pneumonia model but not in the nasopharyngeal
colonization model and, in contrast to the serotype 3 0100993
livHMGF strain, had only a statistically not significant (the
confidence intervals overlapped with 1.0) small decrease in the
CI for the systemic model of infection. To assess the ability of
the livHMGF S. pneumoniae strain to cause fatal disease,
groups of 10 CD1 mice strain were inoculated i.n. with 107
CFU of the wild-type S. pneumoniae 0100993 strain or the
livHMGF deletion strain, and the progress of infection was
monitored (6) (Fig. 3A). There was no difference in the sur-
vival of mice inoculated with the wild-type and livHMGF
strains, demonstrating that despite the impaired virulence of
the livHMGF strain when in competition with the wild-type
strain this strain is still able to cause fatal disease. In addition,
bacterial CFU in mouse lungs culled 48 h after inoculation
of either the wild-type or livHMGF strains were not sig-
nificantly different (Fig. 3B). These data show that the loss
of LivJHMGF only impairs virulence significantly in a com-
petitive model of infection.
In vitro phenotypes of the livHMGF strain. When com-
pared using the OD580, the growth of the livHMGF mutant
strain was similar to the growth of the wild-type strain in THY
and in a defined chemical medium CDEM with or without
supplementation with the BCAAs valine, isoleucine, or leucine
(data not shown). As shown for the Sp0750 IDM mutant
strain (Table 4), the CI of the livHMGF mutant strain com-
pared to the wild-type strains in vitro after growth in blood was
impaired (CI  0.56, confidence intervals of 0.34 to 0.78), but
this was not corrected by the addition of 10 mg of valine,
isoleucine, or leucine/ml impaired (CI  0.44, confidence in-
tervals of 0.15 to 0.74). Uptake of azaleucine by BCAA ABC
transporters causes toxicity and impaired growth of gram-neg-
ative bacteria (14, 18), which is reduced if BCAA uptake is
inactivated. However, azaleucine in concentrations of up to
100 g ml1 was not toxic to S. pneumoniae (data not shown),
and azaleucine toxicity could not therefore be used to assess
FIG. 2. (A) Structure of the livJHMGF locus. Each arrows represents one gene and contains the Sp number within the arrow and the gene
annotation above the arrow. The size in base pairs of each gene is given below the arrow, and the number of base pairs between the stop codon
of the upstream gene and the ATG of the downstream gene is given above the arrows in the corresponding gap. (B) Results of RT-PCR assessment
of the transcriptional linkage between the livJHMGF genes. The bar represents the target product relative to the genes shown in panel A for each
primer pair (named beneath the bar). A picture of the ethidium bromide-stained agarose gels showing the PCR products obtained using these
primers and either DNA or cDNA as the template is given with each primer pair. (C) Representation of the structure of the livJHMGF locus in
the livHMGF strain. (D) Ethidium bromide-stained agarose gels showing the PCR products obtained from the livHMGF and wild-type strain,
confirming replacement of the livHMGF with the erythromycin resistance cassette (eryr in the figure) in the livHMGF strain. Bars represent
expected products for the primer pairs given above the lanes for their corresponding PCR products.
TABLE 5. In vivo phenotype analysis of the livHMGF
S. pneumoniae strains compared to the wild-type strain
using CI values for three different serotype backgroundsa
Capsular
serotype
CI (95% confidence interval) obtained by various routes
n.p. (nasal wash) i.n. (lung) i.p. (spleen)
3 NDb 0.11 (0.004–0.58) 0.076 (0.040–0.094)
4 1.05 (0.68–1.41) 0.018 (0.001–0.34) 0.62 (0.16–1.08)
a For these experiments, n  5 to 10. n.p., nasopharyngeal.
b ND, not done (there was no nasopharyngeal model for this strain).
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BCAA uptake. Furthermore, attempts to confirm that livJHMGF
does encode an BCAA ABC transporter by comparison of
leucine and isoleucine uptake by the wild-type and livHMGF
strains were unsuccessful. Although significant uptake of the
positive control substrate maltose was demonstrated for both
the wild-type and the livHMGF strains, no significant uptake
of [14C]leucine (Table 6) or [14C]isoleucine (data not shown)
could be detected under these experimental conditions even by
the wild-type strain, precluding the use of uptake assays to
assess the function of LivJHMGF.
LivJ is a BCAA binding protein. Since the SBP component
provides substrate specificity for ABC transporters, to identify
the substrate(s) of the LivJHMGF ABC transporter the bind-
ing of labeled amino acids to the LivJ (Sp0749) SBP was
assessed. An N-terminally histidine-tagged LivJ (His6-LivJ)
was expressed in E. coli and purified to ca. 95% purity. Sodium
dodecyl sulfate-polyacrylamide gel electrophoresis demon-
strated that most of the purified protein was found in a single
band of 40 kDa, which is compatible with the expected mass
for His6-LivJ. There was an additional band with a mass of80
kDa. Peptide mass fingerprinting confirmed that the 40-kDa
band was His6-LivJ and that the 80-kDa band consisted of a
dimer of His6-LivJ. The ligand-binding properties of His6-LivJ
were investigated by measuring changes in intrinsic protein
fluorescence, using tyrosine fluorescence (excitation at 280
nm) since the protein lacks any tryptophan residues. We were
able to observe small but reproducible protein-dependent flu-
orescence changes in His6-LivJ upon the addition of 0.32 M
isoleucine, 3.2 M leucine, and 16 M valine (Fig. 4). There
was no further fluorescence change with the addition of excess
ligand, suggesting binding was saturated (Fig. 4). There were
also no changes in fluorescence with the addition of 50 M
concentrations of the non-BCAAs proline, glycine, and alanine
(data not shown). To estimate a relative affinity of the protein
toward these three BCAAs, the lowest concentration of ligand
for which we could detect a fluorescence change over the slow
decrease in signal due to photobleaching was determined. Us-
ing 1.6 M concentrations of ligand we could only detect
isoleucine and leucine binding, and using 0.32 M concentra-
tions of ligand we could only detect isoleucine binding (Fig. 4
and data not shown). These data suggest that LivJ (Sp0749) is
able to bind BCAA with a preference for isoleucine over
leucine over valine and that the protein is likely to bind iso-
leucine in the submicromolar range that is typical for the phys-
iological substrate of other ABC transporters.
The ligand-binding properties of His6-LivJ were also inves-
tigated by using a radioactive binding assay. The His6-LivJ
lipoprotein bound to [14C]isoleucine and to a lesser extent
[14C]leucine but not to the negative control ligand [-14C]amino-
isobutyric acid (AIB) (Fig. 5A). Competitive binding experi-
ments using putative ligands to inhibit [14C]isoleucine binding
to His6-LivJ protein demonstrated that leucine and, to a lesser
extent, valine and threonine inhibited [14C]isoleucine binding
(Fig. 5B). Overall, the results of the fluorescence and radioac-
tive binding studies show that the substrates of the S. pneu-
moniae LivJHMGF ABC transporter are BCAAs, with high-
affinity binding of LivJ to isoleucine, moderate affinity binding
to leucine and the least affinity toward valine.
DISCUSSION
Genes encoding components of ABC transporters make up
a significant portion of many bacterial genomes, including S.
pneumoniae (12, 40). Through controlling uptake or export of
a wide range of substrates, ABC transporters have a central
role in modulating the bacterial interactions with the environ-
ment, including the host for pathogens. Hence, it is perhaps
not surprising that STM screens for virulence determinants
frequently have identified ABC transporters (9, 10, 15, 22, 26)
and that detailed characterization of individual S. pneumoniae
ABC transporters have shown that several affect the develop-
ment of infection through a variety of mechanisms (6, 17, 27,
34, 44). We have screened 11 S. pneumoniae ABC transporters
that have not, as far as we are aware, previously been investi-
gated for their roles in virulence. Mixed infections and CIs are
TABLE 6. 14Cleucine and 14Cmaltose uptake by wild-type and
livHMGF strains
Strain Substrate
Uptake (mmol/mg of protein) at:
60 s 120 s 180 s
Wild type 14Cleucine 0.44 0.47 0.35
14Cmaltose 12.8 30.4 40.4
livHMGF 14Cleucine 0.41 0.62 0.71
14Cmaltose 13.0 32.7 44.6
FIG. 3. Assessment of the virulence of the livHMGF strain in
mouse models of infection. (A) Time course for the development of
fatal infection for groups of 10 mice given 5  106 CFU of either the
wild-type or the livHMGF strain (P  0.88, log-rank test). (B) Log10
ml1 bacterial CFU recovered from the lungs of mice 24 h after
inoculation with 5  106 CFU of either the wild-type or livHMGF
strain. The results are shown as box-and-whisker diagrams of the
median log10 ml
1 bacterial CFU and the interquartile range for data
obtained from two identical experiments, each with five mice per
strain.
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highly sensitive at identifying virulence defects and only re-
quire relatively small numbers of animals and so were used to
assess the relative virulence of mutant strains containing dis-
rupted ABC transporter genes to the wild-type strains (5, 6).
We were unable to obtain any mutants affecting the putative
amino acid transporter encoded by Sp0707-0711, perhaps since
this transporter is important for S. pneumoniae viability, and
the insertional duplication mutant affecting the putative phos-
phate transporter encoded by Sp2084-2087 was too unstable
for further investigation. Of the nine ABC transporter mutant
strains successfully constructed, six were impaired in full viru-
lence in mouse models of sepsis and/or pneumonia (Sp0090,
Sp0149, Sp0610, Sp0750, Sp1824, and Sp2108). Their
putative roles included sugar, cation, BCAA, and other amino
acid transport, and for the majority the CIs in blood were
similar to the CIs in the infection model, suggesting that their
effects on virulence are likely to be due to their role during
growth under physiological conditions. These results indicate
that ABC transporters frequently influence S. pneumoniae
disease pathogenesis, demonstrating why mutations affect-
ing lipoprotein and therefore SBP processing by S. pneumoniae
affect virulence (21, 29). The majority of the loci encoding
ABC transporters investigated in the present study have equiv-
alents in other streptococci, and it is likely that some of these
will also be required for full virulence.
For four of the ABC transporter mutant strains the impair-
ment in virulence was relatively small, comparable to the effect
of the loss of a single iron transporter (17), and this may be
because their functions are partially redundant. For example,
BLAST alignments suggest that several of the ABC transport-
ers we have investigated encode sugar transporters, and dis-
rupting the function of one could be compensated for by the
others or even by non-ABC transporter uptake mechanisms
such as phosphoenolpyruvate-dependent sugar transporters
(40). In addition, in the host there are a variety of sugar
substrates available, and the inability of S. pneumoniae to use
a single sugar due to impaired uptake may not be critical due
to the availability of other sugars. Dual mutations in genes
encoding components of ABC transporters with related func-
tions may have a much more marked effect on virulence as has
been shown for the Piu and Pia iron transporters (6). However,
too few functional data on the ABC transporters were inves-
tigated here to be able to determine which ABC transporters
should be selected for dual mutation. The effects of disruption
of these ABC transporters on virulence indicates bacterial
functions that are likely to be important during infection,
which our data suggest includes sugar, amino acid, and cation
uptake. Although cation uptake is a well-recognized require-
ment for the virulence of S. pneumoniae and other bacteria (6,
17, 20, 25), sugar and amino acid transport is less well recog-
nized. Identification of the specific substrate for each trans-
porter will help define the precise physiological requirements
for S. pneumoniae virulence but will require painstaking
screening of a range of potential substrates using in vitro phe-
notypes and binding and uptake assays. In addition to ABC
transporters encoded for by groups of genes investigated in this
and previous studies, there are many additional ABC trans-
porter components encoded by isolated single genes or gene
pairs within the TIGR4 genome, some of which STM screens
suggest may affect virulence (15, 22). These ABC transporter
components also warrant further investigation, although their
specific putative functions will in general be even less apparent
than those encoded by several adjacent genes in putative
operons.
Two mutant strains had a marked effect on virulence when
analyzed using CIs. One contained a disrupted copy of Sp0149,
part of a potential methionine transporter which is the subject
of continued investigation in our laboratory. The second con-
tained a disrupted copy of Sp0750, part of an operon whose
FIG. 4. Tryptophan fluorescence spectroscopy of purified His6-LivJ
after addition of 0.32 M isoleucine (A), 3.2 M leucine (B), or 16 M
valine (C) (marked by the first arrow). The addition of excess ligand
(marked by the second arrow) had no further effect on fluorescence,
nor did the addition of 50 M proline, glycine, or alanine (data not
shown). Fluorescence was measured by using arbitary units and an
excitation wavelength of 280 nm with an emission wavelength of
309 nm.
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function is strongly indicated by BLAST searches to be BCAA
uptake. The genes at the Sp0749-53 loci are annotated as
livJHMGF in the TIGR4 genome (40) and are organized in a
fashion similar to that of the equivalent BCAA of E. coli, with
the SBP component encoded by livJ that is transcribed as a
separate transcript to the remaining genes within the operon
livHMGF (19). Tryptophan fluorescence spectroscopy and ra-
dioactive binding assays using [14C]leucine, [14C]isoleucine,
and [14C]valine demonstrated that LivJ binds specifically to
BCAA, strongly supporting that livJHMGF encodes a BCAA
ABC transporter. Both the tryptophan fluorescence spectros-
copy and the radioactive binding assays suggest that LivJ has
the highest affinity for isoleucine and then leucine, with the
least affinity for valine.
Growth of the livHMGF strain was not affected in media
depleted in BCAA, the toxic BCAA analogue azaleucine did
not impair S. pneumoniae growth, and we were unable to
identify significant uptake of the BCAA leucine by S. pneu-
moniae. Hence, in the conditions used for these experiments
(i.e., the complete medium THY and the defined medium
CDEM) there seems to be very little BCAA uptake by S.
pneumoniae. In contrast, in mouse models of infection the
livHMGF and the IDM mutant strain with a disrupted copy of
livH were both significantly outcompeted by the wild-type
strain. These data suggest that there is an important role for
the S. pneumoniae BCAA specifically during in vivo growth, a
conclusion that is supported by previous publications which
have shown that disruption of BCAA synthesis affects the vir-
ulence of the unrelated pathogens B. pseudomallei and M. bovis
(3, 24). However, the effect of loss of LivHMGF on virulence
was only detectable in competitive infection experiments, and
after i.n. inoculation with either the livHMGF or wild-type
strain, bacterial CFU in target organs and progression of in-
fection were similar. When transferred to the TIGR4 strain,
the livHMGF deletion affected virulence in the pneumonia
model but not in the model of systemic infection, a surprising
result given that the effect on virulence was most marked in the
systemic model for the serotype 3 strain. These data have no
immediately apparent explanation and provide further evi-
dence that the effect of mutations of S. pneumoniae genes
depends on strain background. Overall, the data suggest that
LivJHMGF does not have a powerful effect on S. pneumoniae
disease pathogenesis, perhaps because the S. pneumoniae ge-
nome contains genes encoding enzymes required for BCAA
synthesis (Sp0445-50) (24, 40). These may partially compen-
sate for impaired BCAA uptake in vivo, perhaps to a variable
degree between strains, so the effects of the livHMGF muta-
tion on in vivo growth are only detectable if competing against
a wild-type strain and depend on strain background. Exactly
why the loss of BCAA affects virulence is not clear. The most
obvious explanation is a nutritional requirement for BCAA in
vivo, and the differences in CI between sites could be explained
by variations in bacterial demand for BCAA, perhaps related
to differences in bacterial replication rate in combination with
host physiology. However, there was a marked difference in CI
between growth in blood and during infection for the Sp0750
mutant strain, whereas other mutant strains with reduced CIs
in blood only had weakly reduced CIs during infection. These
data perhaps indicate that the loss of virulence associated with
mutation of LivJHMGF may be more complex than simple
impaired growth under physiological conditions. The impaired
CI of the livHMGF strain compared to the wild-type strain
when cultured in blood was not improved by the addition of
exogenous BCAAs. This would be the expected result if
LivJHMGF is a BCAA ABC transporter and there are no alter-
native S. pneumoniae low-affinity BCAA transporter systems
that could compensate for a BCAA transport defect when
BCAAs are present in high concentrations in the environment.
Genes from both the livJHMGF and the Sp0445-50 operons
have increased expression in cerebrospinal fluid in a rabbit
model of meningitis (28) and are under the negative control of
the transcriptional regulator CodY (16), but the relationship
FIG. 5. Radioactive binding assays to purified His6-LivJ. (A) Degree of binding of
14C-AIB (negative control) and the BCAAs [14C]leucine and
[14C]isoleucine to His6-LivJ expressed as pmol of substrate per mg of His6-LivJ. No significant binding to AIB was detected. For the differences
between [14C]leucine and [14C]isoleucine, P  0.023 (Student t test). (B) Competitive blocking of [14C]isoleucine binding to His6-LivJ by the
addition of excess (500 M) AIB, leucine, valine, or threonine. Compared to AIB, P 0.005 for leucine, 0.014 for valine, and	0.001 for threonine.
Compared to leucine, P 	 0.05 for both valine and threonine (one-way analysis of variance).
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between CodY repression, in vitro and in vivo expression of
livJHMGF, and BCAA transport requires further investigation.
To conclude, we have investigated whether a range of S.
pneumoniae ABC transporters affect virulence and identified
that six of the nine investigated had some effect on the patho-
genesis of infection compared to the wild-type strain using
competitive infection experiments. The effects on virulence
were generally weak, probably due to redundancy compensat-
ing for loss of function of individual ABC transporters. The
functions of the majority of the ABC transporters affecting
virulence were not clear, but we have characterized one en-
coded by livJHMGF in more detail and confirmed that it en-
codes a BCAA ABC transporter. Further investigation is re-
quired to identify the substrates of the remaining ABC
transporters and to define why BCAA uptake is important for
S. pneumoniae virulence.
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